[Long-term virus suppression. Expanding therapy options with protease inhibitor].
出版信息
MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:68-9.
PMID:16385882
Abstract
摘要
相似文献
1
[Long-term virus suppression. Expanding therapy options with protease inhibitor].
MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:68-9.
2
[Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:84-5.
3
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.
4
[Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:60-1.
5
Four posters add to our knowledge of Lexiva.
Proj Inf Perspect. 2008 Dec(47):7-8.
6
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med. 2003 Dec 11;145(50):61.
7
[FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:92-3.
8
FDA approves Lexiva.
IAPAC Mon. 2003 Nov;9(11):280.
9
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13.
10
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9.
Zotero 插件